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Tight junctions (TJs) regulate the passage of ions and molecules through the paracellular pathway in epithelial and endothelial cells. TJs are
highly dynamic structures whose degree of sealing varies according to external stimuli, physiological and pathological conditions. In this review
we analyze how the crosstalk of protein kinase C, protein kinase A, myosin light chain kinase, mitogen-activated protein kinases, phosphoinositide
3-kinase and Rho signaling pathways is involved in TJ regulation triggered by diverse stimuli. We also report how the phosphorylation of the main
TJ components, claudins, occludin and ZO proteins, impacts epithelial and endothelial cell function.
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Epithelia are the frontier between the internal milieu of the
organism and the external environment constituted either by the
air or water that surrounds the individual in case of the skin, or
the content of an internal cavity or duct. In multicellular organ-
isms, ducts and cavities covered by epithelia, allow the indi-
vidual to maintain in a separated fashion contents so diverse as
urine, blood, gastric juice, bile, milk etc. The vectorial transport
of ions, water and molecules through epithelia regulates the
composition of body fluids and in consequence the uptake and
removal of multiple ions and substances from the body. In order
to traverse an epithelium two ways are available: the trans-
cellular and the paracellular routes. To cross through the trans-
cellular pathway, the molecule needs to be hydrophobic to
traverse the plasma membrane or alternatively to count with a
specific transport mechanism such as a channel, pump, carrier or
cotransporter. Passage through the paracellular route is instead
regulated by a structure named the tight junction (TJ), located atthe limit between the apical membrane facing the lumen and the
basolateral surface in contact with the interior of the organism.
TJs observed by transmission electron microscopy (TEM)
appear as sites where the intercellular space between neighbor-
ing cells is obliterated and the adjoining membranes appear to
fuse [1]. By freeze–fracture (FF) TJs are detected as a network of
strands that encircles the cell bellow the apical surface [2].
The barrier function of TJs allows this structure to regulate
by size and charge the transit of ions and molecules through the
paracellular route [3]. The permeability through the paracellular
pathway can be evaluated by two methods, the measurement of
transepithelial electrical resistance (TER) [4] and the flux of
tracers that can be detected either for being electron-dense (e.g.,
lanthanum, ruthenium red) and hence observable by the electron
microscope or for having a fluorescent (e.g., FITC–dextran) or
radioactive label (e.g., 3H-mannitol). The size of the TJ pores
can be evaluated employing paracellular tracers of different
sizes while the ionic selectivity of the TJ can be determined
measuring dilution potentials.
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limits the free movement of lipids and proteins within the
plasma membrane between the apical and the basal surface
[5,6]. Recently, another role for TJ has begun to be unraveled. It
involves the control of cell proliferation and gene expression
and requires the shuttling of TJ associated proteins from the
plasma membrane to the nucleus [7].
TJs are integrated by a complex array of integral and peri-
pheral proteins which associate to diverse molecules involved in
signaling cascades, such as G proteins, kinases and phospha-
tases. These interactions allow the cells to transmit information
on the degree of cell–cell contact to the cell interior. A signi-
ficant body of evidence has accumulated in recent years
indicating that the crosstalk of diverse signaling pathways
regulate the formation as well as the disassembly of TJs. In this
review we will focus on how several signaling pathways
modulate the barrier function of the junction and how particular
molecular constituents of the TJ are phosphorylated by diverse
kinases. To accomplish this task wewill start by providing a brief
description of the main TJ proteins.
2. Brief description of the molecular constituents of the TJ
TJs are multiprotein complexes composed of integral
proteins that associate with cytoplasmic plaque proteins. The
former mediate cell–cell adhesion, while the latter function as a
bridge between the TJ and the actin cytoskeleton (for extensive
reviews, see [8,9]). Here we will only describe the main char-
acteristics of the ZO proteins, occludin and claudins since their
interaction with kinases, phosphatases and small G proteins has
been more thoroughly studied.
2.1. ZO proteins of the TJ
ZO-1, ZO-2 and ZO-3 are members of the MAGUK
(membrane-associated guanylate kinase) protein family and
are an important subgroup of the PDZ proteins of the TJ (for
reviews, see [10,8]). ZO proteins are identified for having an
amino domain that contains the characteristic features of all
MAGUK proteins: PDZ domains, followed by SH3 and GuK
regions; and a carboxyl end that includes an acidic domain and a
proline-rich region. In ZO-3 the latter is located between PDZ-2
and PDZ-3.
ZOs are peripherally associated membrane proteins whose
name derives from the initials of zonula occludens, the Latin
name for TJs, and whose number reflects the order in which they
were originally identified (for a review on these proteins, see
[10]). These proteins interact together and anchor membrane
proteins like claudins, occludin and JAMs to the actin
cytoskeleton. ZO proteins are scaffolds that establish numerous
protein–protein interactions that cluster at the TJ diverse
kinases, phosphatases, small G proteins and nuclear and
transcription factors [11]. ZO-1, ZO-2 and ZO-3 contain several
nuclear localization and exportation signals (NLS and NES)
[11]. ZO-1 and ZO-2 concentrate at the nucleus when subjected
to adverse conditions such as chemical stress or mechanical
injury, or when cells are cultured at a sparse density [12–14].ZO-1 and ZO-2 associate with proteins involved in the
regulation of gene transcription and cell proliferation such as
the transcription factors ZONAB [15], Jun, Fos, C/EBP [16] and
KyoT2 [17], the chromatin component SAF-B involved in the
assembly of transcriptosomes [14], the cell cycle regulator
Cyclin D1 [18] and the heat shock protein Apg-2 [19].
2.2. Claudins
Claudins constitute a family of more than 20 proteins with
four transmembrane domains [20]. They are the major
component of TJ strands observed by FF. Claudins have two
extracellular loops that display variability in the distribution and
number of charged residues. This feature is crucial as it
determines the paracellular ionic selectivity of the TJ. Accord-
ingly, some claudins form paracellular ion channels (e.g.,
claudin-2, is a cation channel [21], and claudin-16 is a Mg2+
channel [22]) while others constitute paracellular ion barriers
(e.g., claudin-8 reduces paracellular Na+ permeability [23]).
Although claudins are found in all epithelial and endothelial
cells, their tissue distribution is specific. For example, the
mammalian nephron displays a wide spectrum of claudins
including claudins-1, -2, -3, -4, -7, -8, -10, -11, -14 and -16
whose distribution varies in each tubular segment (e.g., the
leakier segment of the nephron expresses claudin-2, whereas the
tighter distal tubules exhibit claudins-7 and -8) [24,25].
Endothelial cells also display a claudin-specific distribution.
Thus endothelial cells of the brain express claudins-3, -5 and -12
[26–28], kidney endothelia have claudins-5 and -15 [24,27],
while placental endothelia exhibit claudins-1, -3 and -5 [29,30].
The expression of claudins also varies along the vascular tree.
Thus in the placenta the expression of claudins-1 and -3
diminishes or is even absent in the smaller vessels, while the
expression of claudin-5 is strong in some vessels and absent
from others even of a similar width [29].
2.3. Occludin
Occludin is a TJ protein whose physiological role still
remains controversial. This tetraspan protein has a first
extracellular loop enriched with tyrosine and glycine residues
and a second one full of tyrosines. Occludin is present in the
filaments that constitute TJs [31] and its overexpression or
mutations severely affect TER [32,33], yet occludin knock-out
mice are viable and exhibit TJs with an apparent normal
morphology [34].
3. TJs are regulated by phosphorylation
The relationship between the degree of protein phosphory-
lation and TJ function was first analyzed in the late 1980s by
Stevenson et al. [35], demonstrating how in low resistance cells
the TJ protein ZO-1 is significantly more phosphorylated than
in high resistance monolayers. Since then an enormous amount
of research has been done on the phosphorylation of TJ pro-
teins. For many years, much of the results obtained remained
controversial due to the fact that phosphorylation can be
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on the same TJ proteins. These results are now better
understood thanks to the use of inhibitors and stimulators
specific for certain kinase isoforms and to the analysis by point
mutation of particular phosphorylated residues.
3.1. PKC signaling
Protein kinase C (PKC) has long been recognized to affect
epithelial and endothelial barriers. PKC consists of a family of
Ser/Thr-specific kinases which includes 12 known isozymes that
can be classified into three subfamilies: conventional (α, β1, β2
and γ), novel (δ, ε, θ, η and μ) and atypical (λ, τ and ζ). These
isoforms differ in their mechanism of action, subcellular
distribution, substrate type and expression. Thus conventional
isoforms (cPKC) are both Ca2+ and diacylglycerol (DAG)
dependent, novel isoforms (nPKC) are Ca2+ independent but
DAG dependent while the atypical PKC isoenzymes (aPKC) are
neither Ca2+ nor DAG dependent. At the plasma membrane
the nPKC isoenzymes δ and θ [36], and the atypical isoforms
λ and ζ [36–42], are found associated to TJ proteins (Table 1).
PKC activity can be regulated by other PKCs. Therefore a given
PKC like the cPKCαmay be regulating TJs even though it does
not itself localize directly to the TJ.
3.1.1. PKC and TJ barrier function
The initial studies designed to elucidate the role of PKC on
TJ function were performed employing stimulators and
inhibitors that acted upon several subfamilies of PKC isoforms.
Therefore understanding the role of specific PKC isozymes on
TJs became particularly complex and required the comparison
of results obtained with various PKC affecting drugs on dif-
ferent biological systems.Table 1
Kinases and phosphatases present at the TJ
Kinase/
Phosphatase
Isoform Cell or tissue Associated to
TJ protein
References











ζ MDCK, Caco-2 ZO-1 [40,41]
MDCK ZO-2 [39]
ζ T-84 Occludin [42]
CK Iε HUVEC Occludin [260]
ERK1 Caco-2 Occludin [160]
WNK4 Distal nephron [229]
c-Yes MDCK, T-84 Occludin [269,42]
PI3K T-84, Caco-2 Occludin [42,209]
Con8 ZO-1 [162]
PP2A MDCK ZO-1, occludin,
claudin-1
[125]
Caco-2 Occludin p-Thr residues [126]
PP1 Caco-2 Occludin p-Ser residues [126]
Epithelial cell lines: MDCK, dog renal; Caco-2, human colon; T-84, human colon;
Con8, rat mammary tumor. Endothelial cell line: HUVEC, human umbilical cord.The participation of PKC in TJ assembly is demonstrated by
observing that (1) diC8, a DAG analogue that stimulates
conventional and novel PKC, triggers the translocation of TJ
proteins to the cell borders [43,44]; (2) when cells cultured in
low calcium media (LC, 1–5 μM Ca2+) are switched to normal
calcium (NC, 1.8 mM) media, TER development can be
hampered by inhibitors of conventional and novel PKC such
as staurosporine, calphostin C and Gö6850, and by pan-PKC
inhibitors like GF-109203X and H7 [40,44–47]; (3) EGF and
fetal bovine serum (FBS) promote TJ assembly in cancerous
cells in a process that can be reversed with calphostin C and
Gö6850 [48]; and (4) the bacteria Helicobacter pylori disrupts
the barrier function of intestinal epithelial cells through a process
inhibited by PMA an activator of novel and conventional PKCs
[49].
The participation of PKCs on TJ disassembly has been
studied employing diverse protocols that trigger TJ disruption
such as oxidative stress [50]; removal of Ca2+ from the media
[39,44,51–53]; elevation of intracellular Ca2+ by treatment with
the Ca2+ ionophore A23187 [54], incubation with different
agents such as phorbol esters [55,56]; hepatocyte growth factor
(HGF) [57] and vascular endothelial growth factor (VEGF) [58];
the hormone vasopressin [59]; cytokines tumor necrosis factor α
(TNFα) and interferon γ (IFNγ) [60]; HIV-1 envelope
glycoprotein gp120 [61]; toxins Zot (zonula occludens toxin),
from Vibrio cholera [62] and A from Clostridium difficile [63],
and incubation with OmpA (outer membrane protein A)-positive
Escherichia coli [64] or enterohemorrhagic E. coli (EHEC) [65].
These studies have revealed that inhibitors of classical and novel
PKCs like staurosporine, Gö6850 and CGP41251, as well as the
pan-PKC inhibitors GF-109203X and H7 attenuate the opening
of TJs. Interestingly some of these studies have further shown
that TJ opening is accompanied by the translocation of cPKCα
from the cytoplasm to the plasma membrane [66–69,58,64,62].
In fact, chronic exposure of epithelial LLC-PK1 cells to phorbol
esters results in a partial TER recovery and a reciprocal change in
mannitol permeability. These effects triggered by the chronic
exposure to phorbol esters are due to the downregulation of
cPKCα [68,69].
The effect of phorbol esters that stimulate both cPKC and
nPKC varies on different biological systems. Thus, phorbol
esters improve the TJ barrier function in colon carcinoma (HT-
29) cells [70] and in a certain clone of pig renal cells (LLC-
PK1A) [71]. In mouse pre-implantation embryo phorbol esters
stimulates membrane assembly of ZO-1 isoform α+ [72].
Instead the acute treatment with phorbol esters induces in diverse
epithelial cell lines like LLC-PK1 (renal), MDCK (renal), T-84
(intestine) and HepG2 (hepatic) a decrease in the barrier function
of the TJ manifested by a drop in the TER, an increased
paracellular permeability, the disappearance of TJ proteins from
the cell borders, as well as the appearance of a disorganized
pattern of TJ strands [54,56–58,66,67,71,73–75]. In LLC-PK1
cultures chronic treatment with phorbol esters triggers the
abovementioned recovery of TER as well as the appearance of
multilayered polyp-like foci (PLFs), across the otherwise one
cell layer thick cell sheets. These PLFs have TJs permeable to
ruthenium red and exhibit cPKCα in the membrane-associated
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normal epithelium that has sealed TJs and no discernible
cPKCα expression [68,69]. In the choroid plexus epithelium the
alteration of TJs induced by phorbol esters can be blocked with
Rottlerin, a specific inhibitor of nPKCδ, thus suggesting
participation of this isozyme in TJ disassembly [76].
The role played by PKCδ and α on TJs is complex and seems
to vary according to the cellular context. For example, the
overexpression nPKCδ in renal LLC-PK1 cells exerts a negative
effect on the TJ barrier [73]. In contrast rottlerin blocks in
MDCK cells the formation of the TJ barrier triggered by Ca2+
[44], and in the intestinal epithelial cells HT-29 and Caco-2, the
stimulation of Toll-like receptors 2 (TLR2) with specific ligands
leads to the activation of the cPKCα and the nPKCδ, the
development of an enhanced TER and the translocation of ZO-1
to the TJ [77]. These effects could be blocked with rottlerin and
the cPKC inhibitor Gö6976. Taken together these results
indicate that in some tissues like the choroid plexus epithelium
and LLC-PK1 cells, nPKCδ and cPKCα promote TJ degrada-
tion while in others such as HT-29, Caco-2 and MDCK these
isozymes favor TJ formation (Fig. 1).
The importance on TJ formation of novel and atypical PKC
isoforms δ and ζ has been highlighted in studies done in mouse
pre-implantation embryos where these isozymes concentrate at
the TJ [36]. In immunosurgical isolated inner cell masses (ICM),
membrane assembly of ZO-1α+ and ZO-2 triggered by
indolactam, an alkaloid activator of cPKC and nPKC iso-
enzymes, and of ZO-1α+ elicited by TPA, can be blocked with
the pan-PKC inhibitor Gö6983, and the conventional and novel
inhibitors Ro-31-8220 and Ro-31-8425, but not by Gö6976, an
inhibitor of cPKC isoforms [72]. These results thus suggest that
nPKCδ and aPKC but not cPKCs, play a central role in TJ
formation (Fig. 1). This proposal was further confirmed when
specific inhibitors of nPKCδ (translocation inhibitor peptide)Fig. 1. Different PKC isozymes are involved in TJ opening and assembly. The name o
tested is indicated.and aPKCζ (pseudosubstrate peptide) blocked the assembly of
ZO-2, and inhibiting the activity of aPKCζ attenuated ZO-1α+
assembly [78]. In contrast to these observations, E. coli Nissle
1917 (EcN), which has been employed for decades for the
treatment and prevention of intestinal disorders in Central
Europe, restores the epithelial barrier disruption generated by
enteropathogenic E. coli (EPEC) strain, by silencing the aPKCζ
and triggering the enhanced expression of ZO-2 and its
redistribution towards the cell borders [79].
nPKCθ also appears to be crucial for TJ stability as its under
or overexpression in Caco-2 cells reduces the monolayer barrier
function, the presence of claudins-1 and -4 at the plasma
membrane as well as their degree of serine and threonine
phosphorylation [80].
Bryostatin 1, a non-phorbol ester stimulator of cPKCα, and
the nPKCε and δ, is a relatively novel pharmacological tool to
uncover the role that different PKC isoforms play in junction
physiology. Thus in LLC-PK1 epithelial cells, bryostatin 1
causes only a 30% decrease in TER which spontaneously
reverses after 5 h. This effect can be explained by the fact that in
contrast to TPA, bryostatin 1 triggers a slower translocation of
cPKCα from the cytosol to the membrane and a much more
rapid downregulation of cPKCα, with disappearance from this
compartment after only 6 h [67]. Moreover, in the human
intestinal cell line T-84, bryostatin 1 increases TER, shifts the
subcellular distribution of claudin-1 and ZO-2 from a detergent
soluble to an insoluble fraction and triggers the appearance of
phosphorylated occludin [81]. Since bryostatin 1 induces rapid
and sustained activation of the δ and ε nPKC isozymes in T-84
cells after 30 min and only activates cPKCα after 3–4 h
followed by downregulation [82], it has been proposed that the
activation of either nPKC δ or ε triggers the increased TER.
However, since bryostatin 1 effect can be attenuated with the
novel and cPKC inhibitor Gö6850, but not with the cPKCf the PKC isozyme involved and the cell line or tissue where the kinase effect was
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concluded that nPKCε signaling promotes the barrier function
of TJs [81].
Another evidence that suggests the participation of different
PKC families on TJ formation and disruption arose with the
observation that in MDCK cells the phosphorylation of
occludin and the appearance of TJ proteins at the cell borders
triggered by diC8 are potentiated by Gö6976, an inhibitor of
cPKCs, and blocked by rottlerin, an inhibitor of the nPKCδ.
In summary we can conclude that in general cPKC
participate in junctional disassembly while novel isoforms
regulate junction formation [44]. However, since contradictory
effects are found in different cell models, both cultured cell lines
and tissue, in Fig. 1 we provide a scheme that summarizes
which PKC isozyme promotes TJ opening or assembly in each
particular cell system.
3.1.2. PKC and the development of cell polarity
Apicobasal polarity is a crucial characteristic of epithelia that
allows the vectorial transport of ions and molecules between the
external media and the interior of the organism. Three molecular
complexes are responsible for cell polarity: Par3/Par6/aPKC,
Crumbs/Pals/PATJ and Scribble/Disc Large/Lethal Giant Lar-
vae (Lgl). Here we will concentrate on the first as we are
particularly interested in analyzing the impact of kinases on the
regulation of TJ formation, and since Par6 and aPKC regulate
the other two polarity complexes [83–85].
Par3/Par6/aPKC is an evolutionary conserved complex
crucial for anterior–posterior polarity in Caenorhabditis
elegans and the apical–basal polarity of epithelial cells and
neuroblasts in Drosophila melanogaster [86,87]. In mammalian
epithelial cells, this complex is found at the apical end of the
junctional complex where TJs are located. Introduction of a
kinase defective aPKC mutant blocks the contact induced
formation of junctional structures and inhibits the development
of cell surface polarity [88,89]. Par3 exhibits an aPKC binding
site, and a PKC phosphorylation site (Ser827) that becomes
phosphorylated presumably by the aPKC during the initial
phase of TJ formation [90]. Par3 associates directly with the TJ
protein JAM and this interaction appears to tether the Par3/Par6/
aPKC complex to TJs [91] (Fig. 2).
Par6 is a scaffolding protein whose single PDZ domain
associates with the N-terminal PDZ of Par3, a protein contain-
ing 3 PDZ domains. At the amino terminal portion of Par6, a
PB1 (Phox and Bem1p) region is located that heterodimerizes
with a PB1 domain present in aPKC. A CRIB motif present in
Par6, downstream of the PB1 domain, associates with active
Rho proteins. This interaction enhances the kinase activity of
the aPKC [89]. ECT2, a guanine nucleotide exchange factor,
interacts directly with Par6 and its overexpression stimulates
PKCζ activity [92]. In confluent MDCK cells ECT2 is detected
in cell–cell junctions and when cells are grown in LCmedium, a
condition where TJs and adherens junctions are lost, the amount
of ECT2 decreases and the protein concentrates at the nucleus
instead of the cell borders [92]. The importance of ECT2 in cell
polarization is highlighted by observing that dominant negative
or constitutively active forms of ECT2 inhibit normal cystformation in MDCK cells cultured in three-dimensional
collagen gels, due to a blockade in the selective elimination
of cells at the center of cysts [93].
A crosstalk between the three polarity complexes has been
detected. This situation is particularly interesting since the
tumor suppressor Lgl concentrates in polarized epithelial cells,
at the basolateral membrane domain, whereas the Par3/Par6/
aPKC complex localizes at the TJ region. The key for
understanding the interaction of these physically separated
complexes lies in observing that the PDZ domain of Par6
selectively interacts with either Lgl or Par3 [84] (Fig. 2). Thus
initial cell contacts recruit aPKCλ/Par6/Lgl complexes to the
cell–cell contact region. Interaction of Cdc42-GTP with Par6
activates the aPKCλ, triggering the phosphorylation and
subsequent segregation of Lgl from the Par6/aPKCλ complex.
In consequence Lgl remains confined to the lateral membrane
region and the formation of the Par3/Par6/aPKCλ complex that
induces TJ formation is promoted.
aPKC and Lgl appear to act antagonistically in the regulation
of the apicobasal polarity in early vertebrate development [94].
Thus, in frog blastomeres the overexpression of aPKC expands
the apical domain at the expense of the basolateral while the loss
of aPKC function or the increased expression of Lgl causes
expansion of the basolateral domain. When aPKC is over-
expressed, the TJ is repositioned to the new apico-basolateral
interface while it is lost when the aPKC is non-functional. The
overexpression of Crumbs, a target of aPKC, causes apicalisa-
tion similar to that observed with aPKC.
The establishment of the Crumbs/Pals/PATJ complex is
affected by the Par6/aPKC complex since the association of
Cdc42-GTP to Par6 regulates the interaction of the amino
terminus of Pals1 with the PDZ domain of Par6 [85]. This
association affects the formation of the Crumbs/Pals/PATJ
complex, as it competes PATJ binding to Pals1. Furthermore,
aPKC directly associates to both Crumbs and PATJ, and the
former is a phosphorylation target of aPKC. This phosphory-
lation is required for the development of epithelial cell polarity
in Drosophila [95].
In endothelial cells, Par3 and Par6 form a complex with
endothelial cadherin (VE-cadherin) that lacks aPKC. Yet this
complex localizes to adherens junctions and promotes cellular
polarization [96].
3.2. PKA and PKG signaling to TJs
Signaling by protein kinase A (PKA) has long been known to
regulate both the assembly and opening of the paracellular route
in epithelial and endothelial cells. PKA activity is promoted by
treatment with permeable cAMP (e.g., dibutyryl cAMP) or with
drugs that activate the enzyme adenylyl cyclase (e.g., forskolin),
or that inhibit the phosphodiesterase (e.g., xanthines), and in
consequence raise the intracellular level of cAMP.
PKA activation as well as phosphomimetic mutations done
in PKA targets sites of TJ proteins block the development of
the TJ barrier during a Ca2+ switch in MDCK and human
ovary cells [45,97], lower the TER of gallbladder, Sertoli and
MDCK cells [98–100] and induce size selective loosening in
Fig. 2. Schematic model of interaction of aPKCwith protein complexes involved in the genesis of cell polarity in epithelial cells. Upon establishment of the initial cell–
cell contacts activated Cdc42 enhances aPKC activity, phosphorylating Lgl. This phosphorylation segregates Lgl from the Par6/aPKC complex promoting the
formation of a new complex integrated by Par6/aPKC/Par3 that binds to the TJ protein JAM and promotes TJ formation. Segregated Lgl remains in the lateral
membrane promoting the growth of this membrane domain.
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HA-1104 preserve the TJ barrier of mammary epithelial
cells [102] and block the hyperphosphorylation of ZO-2 in
MDCK cells [39], upon removal of Ca2+ from the extracellular
medium.
In the BBB astrocytes surround endothelial cells providing
them with a biochemical support. Culture models of endothelial
brain cells have a low TER of 10–120 Ω cm2 and form TJ
networks of low complexity [103]. TER doubles when the cells
are cultured with astrocyte conditioned media or with astro-
cytes, but even a greater effect is obtained by increasing intra-
cellular cAMP, reaching TER values as high as 600 Ω cm2
[104,105]. cAMP stabilizes TJs, decreases permeability and
increases the complexity of junctional strands in a rapid and
reversible manner [104–107]. The addition of astrocyte
conditioned medium together with cAMP changes the associ-
ation of brain endothelial junctional particles, from the E to the
P face of the plasma membrane, resembling the association
pattern observed in epithelial TJs [107,108].In certain epithelia like thyrocytes, hepatocytes and in the
colon epithelial cell line T-84, PKA activation promotes the re-
establishment of the TJ barrier triggered by a Ca2+ switch [109]
and reverses TJ disruption generated by oxidative stress [50]
and extracellular Ca2+ removal [110]. In invertebrates a
somewhat similar effect is detected. Thus in the early and
mid-vitellogenic follicles of the insect Hyalophora cecropia,
treatment with cAMP transforms the loosely organized follicle
cells that allow the intercellular movement of vitellogenin to the
oocyte surface, into a tight epithelium [111].
Rab 13 works as a link between PKA signaling and TJ
assembly [112]. This GTPase is recruited to cell–cell contacts at
an early stage of TJ assembly, binds to PKA, inhibits its activity
and delays the arrival of claudin-1 and ZO-1 to the TJ.
In summary we can conclude that in brain endothelial cells
PKA activation promotes the barrier function of TJs, while in
other endothelia and in epithelial cells a generalization cannot be
made, as PKA can produce contrary actions in different cell
models.
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different effects depending on the state of the tissue. Thus
protein kinase G (PKG) participates in the signaling cascades
that leads to opening of the BBB triggered by hypoxia [113].
Hypoxia induced hyperpermeability is mediated by the in-
teraction of VEGF with its tyrosine kinase receptors (e.g.,
VEGF-R2) [114]. This leads to receptor dimerization followed
by autophosphorylation, which in turn triggers the activation
PI3K/AKT and PLCγ. The latter induces generation of IP3 that
produces an elevation in intracellular Ca2+ that activates nitric
oxide synthase (NOS) to produce NO [115–117]. NO stimulates
soluble guanylate cyclase (GC) leading to increase cGMP, which
in turn activates PKG. Inhibitors of eNOS (e.g., NG-mono-
methyl-L-arginine), GC (ODQ) and PKG (KT 5823) abolish
hypoxia andVEGF induced permeability changes [114,117,118]
as well as the delocalization of ZO-1 and ZO-2 from the cell
borders [113], thus demonstrating that both GC and PKG are
involved in TJ opening in brain endothelial cells triggered by
hypoxia. Hypothermia can decrease hypoxia induced hyper
permeability by lowering the expression of VEGF and with it the
levels of NO and cGMP [119].
In contrast, cGMP and PKG have also been reported to
increase the barrier function of brain endothelial cells. Thus NO
donors (e.g., SNP and DETA NONOate) or cGMP agonists (8-
Br cGMP) increase TER, decrease paracellular permeability,
and are able to reverse the increased permeability triggered by
cytokines in HBMEC cultures [120], or by bradykinin infused
into the carotid artery of rats implanted with gliomas [121].
Accordingly inhibiting cGMP (zaniprast) enhances the effect of
drugs like Cereport, a bradykinin agonist, that increase permea-
bility of the brain microvascular endothelium [122].
The importance of NO signaling in junctional sealing is
further highlighted in the microgravity condition. Thus bovine
aortic endothelial cells (BAEC) and liver WB-F344 epithelial
cells, cultured in rotary wall vessels to stimulate a microgravity
environment, form large cellular aggregates that display an
increase in barrier properties and upregulation of TJ protein
expression, through a process that involves increased basal
production of NO [123,124].
In summary the discrepancy between the results that show
increase TJ sealing by the NO signaling pathway and those
obtained in hypoxia could be due to the fact that in the latter
condition the effect of cGPM and PKG is given under a more
complex background that involves the simultaneous activation
of several other second messengers.
3.3. TJs and phosphatases PP1, PP2A and PP2B
Ser/Thr phosphorylation of several TJ proteins promotes the
barrier function of TJs. Therefore it is expected that reducing the
phosphorylation level of such proteins would negatively affect
TJ integrity. Such appears to be the case since enhancing the
activity of the Ser/Thr protein phosphatase 2A (PP2A) induces
dephosphorylation of ZO-1, occludin, and claudin-1, and an
increased paracellular permeability, while inhibition of PP2A
with okadaic acid promotes the phosphorylation of these TJ
proteins and accelerates junctional assembly [125,126].Protein phosphatases PP2A and PP1 interact with the car-
boxyl terminal tail of occludin (Table 1). PP2A dephosphor-
ylates occludin on Thr, while PP1 dephosphorylates Ser
residues. Na+,K+-ATPase in mammalian cells localizes at TJs
and associates with PP2A. Inhibition of Na+,K+-ATPase ion
transport function reduces PP2A activity and hyperphosphor-
ylates occludin. However, in pancreatic cells, inhibition of
PP2A with ouabain decreases TER and increases paracellular
permeability [127]. Altogether these results suggest that altering
the balance of occludin phosphorylation in Ser/Thr residues
exerts a profound effect on the gate function of TJs.
In the relationship between phosphatases and TJ proteins,
PKC is also involved. PP2A associates with aPKCζ, an isoform
found at TJs. This interaction inhibits the activity of the kinase
and promotes its relocalization to the cytosol. Moreover, the
inhibition of aPKCζ can block the appearance of TJ proteins at
the cellular borders induced by okadaic acid [125]. PP2B in turn
appears to decrease the phosphorylation state of cPKCα, and
treatment with PP2B inhibitor FK506 blocks the recovery of the
thrombin-mediated decrease of TER in pulmonary endothelial
cells [128]. This result is in agreement with previous obser-
vations demonstrating that cPKCα promotes TJ disassembly
[44]. Thrombin-induced TJ barrier disfunction in endothelial
cells is mediated by an increased phosphorylation of MLC that
triggers contraction of the acto-myosin ring. This process
appears to be determined by an increased activity of PP2B
triggered by thrombin, as PP2B inhibitors (e.g., cyclosporin and
deltamethrin) attenuate MLC dephosphorylation [129].
In summary we conclude that Ser/Thr phosphatases exert
opposite effects on the barrier function of TJs by inhibiting
different PKC isoform. Thus PP2A inhibits the aPKCζ involved
in TJ assembly and hence this phosphatase triggers TJ opening,
whereas PP2B blocks the activity of cPKCα that disassembles
TJs and in consequence PP2B promotes TJ sealing.
3.4. Rho signaling and TJ function
Rho is a member of the Ras superfamily of small GTP
binding proteins that switch between active GTP bound and
inactive GDP bound conformations. This process is regulated by
GDP to GTP nucleotide exchange factors and by GTP
hydrolysis stimulated by GTPase activation proteins. Rho
family of GTPases includes RhoA, Rac and Cdc42 that regulate
distinct actin structures in response to diverse signals. The role of
Rho signaling in TJ function has been studied employing
constitutively active mutants, that have a low basal rate of GTP
hydrolysis, and are thereby locked in an active state, and
dominant negative mutants that have a preferential affinity for
GDP. Studies employing both dominant active and negative
mutants of RhoA, Rac and Cdc42 reveal that they all disrupt the
barrier function of TJs, yet the most intense effect is obtained
with dominant active RhoA mutants [130,131].
C3 transferase from Clostridium botulinum, ADP ribosylates
RhoA, but not Rac and Cdc42, and therefore has been employed
to specifically inactivate RhoA. Downstream effectors of RhoA
include the family of Ser/Thr kinases termed p160 ROCK/
ROKb/ROCKI and Rho kinase/ROKa/ROCKII. ROCKs can
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the regulatory myosin light chain (MLC2) or the myosin phos-
phatase target subunit (MYPT) resulting in the inhibition of
myosin phosphatase and hence hyperphosphorylation of
MLC2 (Fig. 3). Several plaque proteins of the TJ interact
directly with actin (e.g., ZO-1, ZO-2, ZO-3, AF-6 and cingulin)
and myosin (e.g., cingulin). Such interactions stabilize the
junctional complex at the cell border and also provide the force
for the disruption of intercellular junctions upon contraction of
the perijunctional acto-myosin ring. Therefore it is no surprise
that the RhoA/ROCK signaling pathway participates both in
the assembly and disassembly of TJs. Hence during ATP
depletion activated RhoA better maintains junctions, while
RhoA inhibition results in a more extensive loss of junctional
components in MDCK cells [132]. Moreover, RhoA inactiva-
tion with C3 transferase disrupts TJ structure and function in
Caco-2, T-84 and MDCK cells [133,134]. In the latter it
inhibits both TJ and adherens junction assembly [135]. Direct
inhibition of ROCK with Y27632 disorganizes the apical ringFig. 3. The crosstalk between PKC, Rho and MLCK signaling pathways regulates T
GDP to GTP on Rho. Activated RhoA signals on its downstream target ROCK resu
cells, BBB impairment is accompanied by Ser/Thr phosphorylation of occludin, c
signaling. Phosphorylation of MLC2 triggers contraction of acto-myosin rings and TJ
of MLCK by PKC inhibits the activity of the former, leading to a decrease phosphory
some epithelia including Caco-2 cells. PKC phosphorylation of MARCKS releases c
T-84 cells the formation of acto-myosin rings that favor de novo junction formationof actin but does not alter TJ protein localization. However, if
ROCK is inhibited during TJ assembly triggered by a Ca2+
switch, TJ proteins fail to redistribute at the intercellular junc-
tions, demonstrating that ROCK is critical for the assembly of
TJ proteins [134].
TJ opening by activation of the RhoA signaling pathway is
triggered by several factors including pro-inflammatory cyto-
kines in intestinal T-84 cells [136], microtubule destabilizing
drugs in human pulmonary artery endothelial cells [137,138]
and the migration of small lung cancer cells through brain
endothelial cells [139]. The expression of pro-inflammatory
cytokines like IFNγ is a hallmark characteristic in the
pathogenesis of inflammatory bowel diseases such as Crohn's
and ulcerative colitis, while the microtubule destabilizing drug 2
methoxyestradiol (2ME), a derivative of the main natural
estrogen 17β estradiol, is currently being tested in the therapy
for several cancers. Therefore understanding the mechanism of
action of these molecules upon epithelial barriers has enormous
clinical importance. Both IFNγ and 2ME activate RhoA,Js. Microtubule depolymerization allows GEF-H1 to stimulate the exchange of
lting in phosphorylation of TJ proteins, MLC2 and MYPT. In brain endothelial
laudin-5, ZO-1 and ZO-2, activation of cPKCα and aPKCζ and Rho/ROCK
disassembly in certain epithelia like MDCK, Caco-2 and T-84. Phosphorylation
lation of MLC2, relaxation of perijunctional acto-myosin and increased TER in
almodulin available for MLCK activation. Phosphorylation of MLC2 triggers in
in sparse cultures and in assembly assays such as the Ca2+ switch.
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lation of MLC2 via a MLCK-independent pathway, TJ dis-
assembly and increased paracellular permeability. In the case of
IFNγ the formation of large actin coated vacuoles (VAC) that
originate from the apical membrane and internalize TJ proteins
occludin, JAM-A and claudin-1 has further been observed [136].
Employment of ROCK siRNAs has served to distinguish the
participation of ROCK2 and not ROCK1 in junctional
disruption triggered by microtubule destabilization with 2ME
[137].
The link between microtubule destabilization and RhoA
activation resides in the nucleotide exchange factor GEF-H1
[140]. This factor that activates RhoA but not Rac or Cdc42
associates with microtubules, and such association inhibits its
activity. Upon microtubule depolymerization by nocodazol or
thrombin treatment, GEF-H1 becomes active stimulating in
consequence RhoA signaling [138,140]. During cytokinesis the
depolymerization of spindle microtubules could speculatively
trigger GEF-H1 activation and the subsequent RhoA/ROCK
signaling, that would then be expected to promote the assembly
of intercellular junctions between the two daughter cells.
Instead in treatments that promote TJ opening by microtubule
destabilization, GEF-H1 stimulation of RhoA is expected to
induce the contraction of acto-myosin rings and the subsequent
endocytosis of TJ components.
GEF-H1 interacts at the TJ with cingulin a plaque protein of
the TJ [141,142]. This interaction inhibits RhoA activation. In
sparse cultures where the expression of cingulin is low, GEF-H1
is cytoplasmic and RhoA is active. Instead, in high density
cultures GEF-H1 is sequestered by cingulin at TJs and RhoA
activation is inhibited.
In summary the abovementioned results suggest that RhoA
activation is important for de novo formation of TJs occurring in
sparse cultures and in monolayers subjected to a Ca2+ switch
assay. The cellular level of activated RhoA is critical for TJ
physiology, therefore overthrowing this balance with pro-
inflammatory cytokines like IFNγ or with microtubule destabi-
lizing drugs, as well as the inactivation of RhoAwith C3 leads to
TJ disassembly (Fig. 3).Fig. 4. Model of myosin II molecule. Myosin II is composed of two heavy chains that
heads project. Two light chains are found around each neck: an essential light chain3.5. Myosin light chain kinase and TJs
The motor protein myosin II is composed of two heavy
chains of 200 kDa each and four light chains of 20 kDa, two
each of so-called essential and regulatory light chains (MLC1
and MLC2, respectively) (Fig. 4). The heavy chains form a
parallel two chain structure with a coiled-coil region termed rod
or tail from which a pair of large globular NH2 terminal heads
project. The heads interact with ATP and actin to generate force
and filament sliding.
The mechanism by which epithelial TJs are disassembled
involves the phosphorylation at serine 19 of MLC2, that leads to
the contraction of the acto-myosin belt. Reducing the extracel-
lular calcium concentration to the micromolar range provokes
the disassembly of tight and adherens junctions through a
process that triggers the centripetal retraction of perijunctional
actin and myosin filaments and the formation of contractile acto-
myosin rings where internalized AJ and TJ proteins are co-
localized [143,144]. This process can be hampered by actin
stabilization (jasplakinolide) or depolymerization (cytochalasin
D or latrunculin A), blocking myosin in an actin detached state
(blebbistatin) or by inhibiting MLCK (ML7). The importance of
MLCK in TJ disassembly is further reinforced by observing that
(1) the overexpression of MLCK catalytic domain increases the
phosphorylation of MLC2, reorganizes perijunctional actin,
alters the distribution of TJ proteins and increases the para-
cellular permeability in epithelial cells [145,146] and (2) the
increased paracellular permeability of epithelial cells triggered
by transfection with the intestinal Na+–glucose cotransporter
SGLT1 [147], incubation with HIV-1 envelope glycoprotein
gp120 [61], infection with EPEC or EHEC [148,65], treatment
with TNFα and IFNγ [148] or bile acids [149] is mediated by
MLC2 phosphorylation by MLCK, as this process is blocked by
MLCK inhibitors ML7, ML9 and PIK. Interestingly the
incubation with the yeast Saccharomyces boulardii that reverses
the increased intestinal permeability triggered by EHEC
abolishes EHEC induced MLC phosphorylation [150].
The assembly of the apical junctional complex is also
dependent on the phosphorylation of MLC2 and requires theform a parallel structure organized as a coiled-coil rod from which large globular
(MLC1) and a regulatory light chain (MLC2).
Table 2











EGF ERK1/2 ND Caco-2 [160]
HGF ERK1/2 ↓ Cl-2 MDCK-II,
94D
[155]
IL-17 ERK1/2 ↑ Cl-1 and
Cl-2
T-84 [157]










Glucocorticoids ERK1/2 None Con8 [162]
Steroids: estradiol and
dihydrotestosterone
ERK1/2 ↑ Occludin HUVEC [164,165]





Epithelial cell lines: MDCK, dog kidney; T-84, human colon; Caco-2, human
colon; 94D, mouse cortical collecting duct; Con8, rat mammary tumor; endothelial
cell lines: HUVEC, human umbilical cord. ↑ Increased or ↓ decreased expression of
indicated TJ protein. Cl, claudin.
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switch assay TJ proteins appear at the cellular borders in co-
localization with actin, actin microfilament nucleation proteins
Arp2/3 and N-WASP (neuronal Wiskott–Aldrich syndrome
protein), myosin II and diphosphorylated MLC2 at Thr18/
Ser19. The amount of the latter increases significantly during
the Ca2+ switch assay. The arrival of TJ proteins to the cell
borders triggered by Ca2+ is blocked by (1) actin depolymer-
ization with cytochalasin D or latrunculin A; (2) the N-WASP
inhibitor, wiskostatin and (3) the myosin blocker blebbistatin,
which also inhibits the ability of epithelial cells to develop a
columnar phenotype with a proper apico-basal polarity.
In summary these results suggest that TJ opening triggered
by incubating cells in LC media, treatment with cytokines, viral
proteins or bacterial infections involves the phosphorylation of
MLC2 in Ser19, that leads to the contraction of the actomyosin
ring, while the diphosphorylation of MLC2 at Thr18/Ser19
triggers de novo assembly of the junctional complex during a
Ca2+ switch assay (Fig. 3). Both processes depend on an intact
cytoskeleton of actin and myosin.
A crosstalk between PKC and MLCK appears to be involved
in the regulation of TER (Fig. 3). Thus, in intestinal cells PKC
activation is accompanied by a progressive decrease in MLC2
phosphorylation. Interestingly an acute increase in MLCK
phosphorylation that occurs concurrently with PKC activation
precedes the decrease in MLC2 phosphorylation and increased
TER [152]. Hence a model has been proposed in which PKC
activation triggers the phosphorylation of MLCK. MLCK
activity is inhibited by intramolecular interactions between its
catalytic domain and the calmodulin binding inhibitory domain.
In the presence of Ca2+ and calmodulin, this intramolecular
interaction is blocked, the inhibition is released and the enzyme
is activated. However, if PKC and PKA target sites present in the
calmodulin binding domain of MLCK are phosphorylated,
MLCK activity is inhibited due to interference with calmodulin-
dependent enzyme activation. Therefore MLCK inactivation
due to phosphorylation by PKC leads to decreased MLC2
phosphorylation, relaxation of the perijunctional acto-myosin
ring and increased TER. In contrast, infection of T-84 cells with
EHEC and treatment of brain microvascular endothelia with
gp120 from HIV-1 induce an opening of TJs through a process
that involves the activation of both PKC and MLCK. These two
signaling molecules could cause the same patho-physiological
outcome acting at different sites within the cytosol, or
alternatively PKC could be regulating MLCK activity by
modulating the availability of calmodulin. In this respect it is
important to note that PKC phosphorylation of MARCKs
(myristoylated alanine-rich C kinase substrate) releases calmod-
ulin bound to MARCKs that is then available for MLCK
activation [153].
3.6. MAP signaling and TJs
Mitogen-activated protein (MAP) kinases are Ser/Thr
protein kinases that respond to extracellular stimuli such as
growth factors and stress, and regulate various cellular activities
including gene expression, mitosis, differentiation and apopto-sis. This signaling pathway has a membranous and a cyto-
plasmic phase. The first occurs in close proximity to the growth
factor receptors and involves the activation of small GTP
binding proteins (i.e., Ras). This is followed by the sequential
activation of several cytoplasmic kinases known as MAPK.
MAP3K is the first kinase in the cascade to become activated,
and as a result phosphorylates a MAP2K on Ser/Thr residues,
and then this MAP2K activates a MAPK by phosphorylation on
its serine and tyrosine residues. MAPK can phosphorylate a
large number of proteins that are located both in the cytoplasm
and the nucleus, including transcription factors that regulate the
transcription of diverse genes.
Four distinct groups of MAPKs are present in mammals: the
first which is activated by growth factors and regulates cell
proliferation and differentiation is integrated by the extracellular
signal-regulated kinases (ERKs) also known as classical MAP
kinases. ERK1 has been found in epithelial cells to interact with
occludin (Table 1). Other two groups of MAPKs activated by
stress stimuli are c-Jun N-terminal kinases (JNKs) and p38
isoforms, which are involved in cell differentiation and
apoptosis. A fourth group named ERK5 has been found to be
activated by both growth factors and stress stimuli and is known
to participate in cell proliferation.
MAP signaling pathway is able to modulate TJ paracellular
transport by up- or downregulating the expression of several TJ
proteins (Tables 2 and 3) and hence altering the molecular
composition within TJ complexes. For example, the activation
of ERK1/2 by transfection with an activated Ras mutant
increases sixfold the transepithelial permeability of mannitol
and more than 40% the TER. This decreased paracellular
permeability to NaCl and increased permeability to a nonelec-
trolyte is not due to loss of junctions as there is a ceiling to the
size of solutes that can cross the barrier (10,000 Da methylated
dextran can cross while 2,000,000 Da methylated dextran
cannot), and instead occurs in response to a decline to unde-
Table 3
MAPK signaling cascade perturbs the barrier function of TJs
Stimulus Activated MAPK Altered TJ protein Cell type References
Ras transfection ERK1/2 Occludin, Cl-1 and ZO-1
disappear from cell borders




Raf transfection ERK1/2, p38 ↓ Cl-2, altered distribution of
ZO-1 at cell borders
Hepatic [167]






ERK1/2 ↓ Occludin, ZO-1 and ZO-2 disappear





Alcohol ERK1/2, JNK, p38 ZO-1 phosphorylation Brain endothelia [168]
CdCl2 p38 ↓ Occludin Sertoli [176]






TGFβ3 ERK1/2, p38 ↓ Occludin, ZO-1 and Cl-11 Sertoli [180,176]
EGF+TGFβ1 ERK1/2 ↓ Occludin and Cl-1 Thyroid
epithelia
[182]
PLGF-1 ERK1/2 ZO-1 disappears from cell borders ARPE-19 [181]
VEGF ERK1/2 ↓ ZO-1 Peritoneal
mesothelia
[178]
TNFα, IFNγ ERK1/2, p38 ↓ Occludin, ZO-1, Cl-2 MDCK [177]
Mast cell tryptase ERK1/2 Occludin and ZO-1 disappear
from cell borders
Colonocytes [189]
HIV-Tat protein ERK1/2 ↓ ZO-1 and Cl-5 Brain endothelia [185,186]
HIV protease inhibitor (ritonavir) ERK1/2 ND HMEC [187]
Matrix metalloproteinases
(MMP-7, MMP-9)





p38 ↓ Occludin and ZO-1 Caco-2 [188]
EPEC ERK1/2 ZO-1 T-84 [190]
Epithelial cell lines: MDCK, dog kidney; ARPE-19, human retinal pigment; PC-1 and PC-1.0, hamster pancreas; AsPC-1, CAPAN-2, human pancreas. Endothelial
cell lines: HMEC, human dermal; HUVEC, human umbilical cord. ↑ Increased or ↓ decreased expression of indicated TJ protein. Cl, claudin.
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claudins-1, -4 and -7 [154]. Moreover, the activation of ERK1/2
by HGF inhibits claudin-2 expression in the leaky strain of
MDCK cells (MDCK II) and increases TER, while the treat-
ment of the tight strain of MDCK cells (MDCK I) with an
ERK1/2 inhibitor induces expression of claudin-2 and decreases
TER by 20-fold [155]. The expression of claudin-2 is parti-
cularly relevant since previous studies had demonstrated that the
difference in junction leakiness between these two strains of
MDCK cells is due to the expression in MDCK II cells of
claudin-2, a protein known to form paracellular cationic channels
[21,156].
In epithelia it has been observed that treatment with the
cytokine IL-17 [157] or with several growth factors including
transforming growth factor β (TGFβ) [158,159], epithelial
growth factor (EGF) [160] and HGF [155], or the exposure of
intestinal cells to bile [161] activates ERK1/2 increasing the
barrier function of TJs. Thiols can also promote TJ sealing by
activating ERK1/2, JNK and p38. Treatment with glucocorti-
coids increases TER by recruiting Ras to regions of cell–cell
contact and inducing ERK1/2 activation [162]. In endothelial
cells endostatin, a 20-kDa fragment of collagen XVIII reverses
VEGF-mediated increase in permeability of the blood retinal
barrier (BRB), through activation of p38 MAPK and ERK1/ERK2 [163]. Interestingly pretreatment of HUVEC cells with
the steroid hormone dihydrotestosterone (DHT), and to a lesser
extent with estradiol (E2), mitigates the permeability defects
associated with brief periods of hypergravity [164,165]. In cells
subjected to conditions similar to those experienced by
astronauts during liftoff, occludin expression is suppressed and
permeability increases. Steroid treatment activates ERK1/2 and
blocks these effects. However, since pretreatment with DHT
induces a longer period of decreased paracellular permeability
after hypergravity than E2, it could explain the higher post-flight
orthostatic intolerance (POI) found in female than in male
astronauts. POI is the failure of the body to properly adjust to an
upright position especially with respect to blood flow, heart rate
and blood pressure, and symptoms of POI can develop as a result
from fluid leakage through the endothelial cell TJ barrier.
Activation of MAPKs is also involved in TJ opening
triggered by Ras [166,154] or Raf transfection [167], treatment
with alcohol [168], bile [149,169,170] oxidative stress, [171–
173], metalloproteinases [174,175], CdCl2 [176], cytokines
TNF∝ and IFNγ [177], growth factors VEGF [178], TGFβ3
[179,180], PLGF-1 [181], and the combined addition of EGF
and TGFβ1 [182], the dissociation factor DF [183,184], HIV-1
Tat protein [185,186] and the HIV protease inhibitor ritonavir
[187], Pseudomona aeruginosa sensing molecule 30-C(12)-
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[189], as well as EHEC [150] and EPEC bacteria [190] (Fig. 5).
The deleterious effect of these bacteria on TJ barrier function is
inhibited by treatment with the yeast S. boulardii that diminishes
the bacteria induced activation of the MAP kinase pathway. The
deleterious effect of EHEC has also been prevented by
pretreating the cells with TGFβ [159].
The action of some of the abovementioned substances is
however subject to variation depending on the tissue studied. For
example, (1) Ras overexpression triggers in MDCK cells the
disappearance of claudin-1, occludin and ZO-2 from cell–cell
contact sites due to ERK1/2 activation, while in breast cancer
cells no changes in the expression of these proteins are detected
[191]; and (2) the addition of bile to rat IEC-6 enterocytic
monolayers increases the expression of TJ proteins and
diminishes paracellular permeability through ERK1/2-depen-
dent signaling [161], while treating human colorectal adenocar-
cinoma Caco-2 cells and primary cultures of bovine pancreatic
ductal cells with bile acids damages the epithelia and diminishes
TER [149,169,170]. This deleterious effect is mediated by
generation of reactive oxygen species (ROS) and the subsequentFig. 5. Activation of the MAPK pathway can lead to TJ opening or assembly depend
indicates the activators of the MAPK pathway that lead to TJ disassembly (red) or th
cascades into three-tiered modules of MAPKKK, MAPKK and MAPK is shown.activation of ERK1/2, p38, PI3K and MLCK [149] and can be
significantly decreased with EGF [170]. Thus it seems that while
the presence of bile in the intestinal lumen favors the normal gut
barrier function, its presence in non-physiological sites like the
colon or the pancreatic duct is deleterious to the organism. In this
respect it should be mentioned that the presence of bile in the
pancreatic duct results in an increase in duct permeability for
molecules up to the size range of pancreatic enzymes and
thereby may contribute to the initiation of gallstone pancreatitis
[169,192,193].
A crosstalk between PKC and the MAPK signaling pathway
also regulates TJ opening. Thus in corneal epithelial cell lines
activation of PKC with PMA triggers a decrease in TER
through the activation of MAPK [194].
JAM-1, a type I protein of the TJ characterized for exhibiting
two extracellular Ig-like domains, appears to constitute a
primary signaling component of the ERK pathway [195].
Thus, JAM-1 silencing hinders the migration of endothelial
HUVEC cells on vitronectin induced by basic fibroblast growth
factor (bFGF), due to the inability of the growth factor to activate
ERK. ERK activation by bFGF is fundamental for triggeringing on the agent that activates the cascade. The uppermost portion of the figure
at favor TJ tightening (blue). The hierarchically organization of MAP signaling
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ture. Interestingly, bFGF signaling involves interaction with
integrin ανβ3, which is known to associate with JAM-1 [196].
Occludin also appears to participate in the activation of the
MAPK signaling pathway [197]. Thus in hepatic cell lines
derived from occludin-deficient mice, MAPK activation is
downregulated triggering apoptosis and increased claudin-2
expression. When occludin is transfected into these cultures
MAPK becomes activated, reversing the increase in claudin-2
expression and apoptosis.
Therefore we can conclude that the MAPK signaling
pathway relates to TJs in two ways: (1) by altering the
expression of several TJ proteins and (2) by the interaction of TJ
integral proteins with other membrane proteins required for the
activation of the ERK signaling pathway.
3.7. PI3K/Akt pathway and TJs
Phosphoinositide 3-kinases (PI3K) are enzymes capable of
phosphorylating the 3 position hydroxyl group of the inositol
ring of phosphatidylinositol [198]. Class I PI3Ks are
composed of a catalytic and regulatory subunits respectively
known as p110 and p85. These kinases convert PI(4,5)P2 to PI
(3,4,5)P3 on the inner leaflet of the plasma membrane. The
presence of PI(3,4,5)P3 translocates Akt, a Ser/Thr kinase,
from the cytosol to the cell membrane. There Akt becomes
activated after being phosphorylated at Ser473 and Thr308 by
the kinases PDK2 and PDK1. Downstream targets of Akt
include the glycogen synthase kinase (GSK-3β), which is
responsible for degrading β-catenin, through the ubiquitin
proteosome pathway, and snail, a transcription factor that
inhibits the transcription of E-cadherin, occludin and claudins.
The lipid phosphatase PTEN antagonizes PI3K signaling as it
dephosphorylates PI(3,4,5)P3 (Fig. 6). PTEN is a known
tumor suppressor, while Akt is involved in cell survival and
proliferation.
PI3K associates to ZO-1 and the carboxyl terminal domain of
occludin in epithelial cells (Table 1) and its activation affects TJ
sealing. For example, PI3K/Akt signaling is involved in the
reduced expression of TJ proteins triggered by treatment with
HIV-1 Tat protein [186] and TGFβ1 [199,200]. The latter
induces an epithelial to mesenchymal transition (EMT) in which
the presence of TGFβ1 triggers (1) the Ras/Raf/Mek/Erk
pathway that leads to c-Jun activation, AP-1 induced snail
transcription, and the subsequent repression of claudins,
occludin and E-cadherin expression; (2) the activation of the
PI3K/Akt pathway that inhibits GSK-3β blocking β-catenin
and snail degradation, generating in consequence the transcrip-
tion of genes regulated by the LEF-1/β-catenin complex
involved in EMT, and repressing the expression of E-cadherin
and TJ genes; and (3) binding of TGFβ to its receptor TβRII
and its heterodimerization with receptor TβRI, followed by the
endocytosis of this complex. In the early endosome TβRI binds
to Smad anchor for receptor activation protein (SARA) which
recruits Smad2/Smad3. Upon phosphorylation by TβRI the
latter are released from the receptor complex and associate to
Smad4. This Smad2/3–Smad4 complex then enters the nucleusand promotes the transcription of LEF-1. PI3K is a mediator of
Smad signaling since the proper association of Smad2/3 with
TβRI requires binding of SARA to PIP3 which is formed by
PI3K (Fig. 6).
Occludin expression appears to trigger the PI3K/Akt
signaling pathway as activation of this route is downregulated
in hepatic cell lines derived from occludin-deficient mice [197].
PI3K signaling is also involved in TJ sealing. Thus in
ischemia-injured porcine ileum the PI3K cascade is required for
prostaglandin induced recovery of TER and the reappearance of
occludin and ZO-1 at intercellular junctions [201], and
tightening of TJ barrier induced by glucocorticoids induces
the recruitment of PI3K subunit p85 to TJs and is attenuated by
PI3K inhibitors [162].
In summary no generalizations can be made on the effect of
PI3K signaling pathway on TJ physiology, as activation of this
route by different agents can induce opposite effects on the
barrier function of TJs.
4. Phosphorylation of specific TJ proteins
4.1. ZO proteins
ZOs are phosphoproteins [43,202]. The analysis of
phosphoamino acids from purified ZO-1 [202] or ZO-2 [39]
reveals a strong phosphoserine signal. In cells lacking TJs due
to the absence of Ca2+ in the media, ZO-2 is significantly
more phosphorylated in serine residues than in monolayers
with well-established TJs. This increased phosphorylation is
due to the action of both protein PKC and PKA [39]. Instead
a hyperphosphorylation of ZO-2 has been reported to
correlate with an increased TER triggered by the PLCγ
inhibitor 3-nitrocoumarin [203]. Since this process is reversed
by the PKC inhibitor staurosporine, it is assumed to involve
Ser/Thr residues. In a similar fashion, the phosphorylation of
ZO-1 diminishes when the assembly of TJs triggered by a
transfer from LC to NC media is blocked with PKC inhibitors
[40].
To our knowledge, the only phosphorylated residue in ZO
proteins whose physiological effect has been studied is Ser369
of ZO-2. This residue is located within NES-1 and complies with
the consensus for phosphorylation by PKC. ZO-2 contains 4
NES which are Leu-rich sequences containing a characteristic
spacing of Leu or other hydrophobic residues. When a peptide
corresponding to the sequence of NES-1 was chemically
conjugated to the reporter protein ovalbumine and injected
into the nucleus, it remained confined to the nucleus, indicating
the lack of functionality of the signal [204,205]. However, if
Ser369 was substituted by a glutamic acid, the reporter protein
left the nucleus through a process sensitive to leptomycin B, an
antifungal compound that inhibits the association of NES with
the export receptor CRM1/exportin. Furthermore, the substitu-
tion of Ser369 for alanine in ZO-2 inhibits the nuclear
exportation of the protein [205]. Since the mutation of any of
the NES present in ZO-2 is sufficient to block the nuclear
exportation of the protein, it is concluded that phosphorylation
of Ser369 is critical for the departure of ZO-2 from the nucleus.
Fig. 6. Schematic representation of the activation of PI3K/Akt kinase pathway and its effect on TJs. The uppermost portion of the figure indicates the activators of the
PI3K/Akt pathway that lead to TJ disassembly (bold) or that favor TJ tightening. PI3K generates phospholipids that activate PDK1 and PDK2. These kinases
phosphorylate Akt rendering it active. Akt phosphorylation deactivates its target GSK-3β, which as a consequence cannot lead β-catenin and snail to degradation in
the proteosome. While snail transcription factor silences the expression of several junctional proteins, β-catenin associates to LEF-1, enters the nucleus and promotes
the transcription of genes involved in EMT. The endocytosis of the TGFβ receptor complex requires PI3K as a mediator of Smad signaling that leads to LEF-1
transcription. The signaling cascade downstream of AKT that promotes TJ tightening is not yet known.
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Interestingly this phosphorylation occurs both under conditions
that favor TJ formation like protamine sulfate treatment of
glomeruli [206], EGF treatment in A-431 cells [207], or ATP
replenishment in MDCK cells [208], and in others that favor the
loosening of the TJ barrier like oxidative stress [209–211], the
transfection of v-Src [212], treatment with HGF [213,214] or
tyrosine phosphatase inhibitors [215] as well as in colorectal
cancer [216].
4.2. Claudins
Claudins are phosphorylation targets of diverse kinases.
Next we will describe several cases in which the phosphory-
lation of claudins alters the barrier function of the TJ, perturbs
the morphological asymmetry in embryos or impacts human
health.4.2.1. Phosphorylation of Thr206 in claudin-1 randomizes the
direction of heart looping
In vertebrates, the positioning of the internal organs relative
to the midline is asymmetric. When a subtractive screen was
done to identify genes that are differentially expressed on the
left and right side of the chick embryo, claudin-1 was identified
as being expressed on the left side. Interestingly, claudin-1
overexpression on the right side of the chick embryos ran-
domized the direction of heart looping. This effect appears to be
regulated by claudin-1 phosphorylation, as it is abolished upon
mutation of Thr206, a residue that constitutes a putative PKC
phosphorylation target [217]. Interestingly this site is conserved
as a putative Thr/Ser PKC phosphorylation site in all the species
where claudin-1 has been sequenced (Fig. 7A). Furthermore,
upon comparing the tail of several claudins we observe that this
residue is conserved as a PKC phosphorylation site in claudins-
2, -7, -8, -16 and -17 (Fig. 7F).
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barrier function of brain endothelia and loosens lung
endothelial TJs
Claudin-5 although present in certain epithelia [218], is
specially concentrated in endothelial cells [27], and in the
blood–brain barrier (BBB) plays a crucial role establishing the
size discrimination of the TJ [28]. In brain endothelia cAMP
increases gene expression of claudin-5, enhances the presence of
the protein along cell borders and promotes in it a switch fromFig. 7. Comparison of phosphorylated residues present in claudins sequenced in diver
claudin-1 with residues present in this segment in other species. (B) Comparison of Th
species. (C) Comparison of Ser217 (blue) present in human claudin-16 with residu
present in human claudin-4 with residues present in this segment in other species. (E) C
this segment in other species. (F) Comparison of the phosphorylated residues presen
correspond to amino acids that constitute putative phosphorylation target sites of
corresponds to the originally described phosphorylated amino acid. Kinase target siSer to Thr phosphorylation via PKA. These effects are accom-
panied by an elevated barrier function of TJs [106]. Instead,
when rat lung endothelial cells are induced to express a claudin-5
with a point mutation in a putative PKA phosphorylation site
(Thr207Ala), they become impermeable to inulin (5 kDa) and
mannitol (182 Da) while the expression of wild-type claudin-5
allows the passage of the smaller tracer, highlighting how the
phosphorylation of Thr207 loosens the size-selective passage of
molecules through the TJ of lung endothelial cells.se species. (A) Comparison of Thr203 (rat, red) and Thr206 (chicken, yellow) of
r207 (blue) present in rat claudin-5 with residues present in this segment in other
es present in this segment in other species. (D) Comparison of Tyr208 (green)
omparison of Thr192 (blue) present in human claudin-3 with residues present in
t in the tail of different claudins from Homo sapiens. The highlighted residues
the same kinase phosphorylating the boxed residue. The highlighted residue
tes: yellow, PKC; blue, PKA; red, MAPK; and green, EpHA2.
Fig. 7 (continued ).
745L. González-Mariscal et al. / Biochimica et Biophysica Acta 1778 (2008) 729–756Although the Thr207 PKA target site present in claudin-5 is
conserved in different animal species, it is absent in other
human claudins (Fig. 7B and F).
4.2.3. Absence of phosphorylation of claudin-16 at Ser217 by
PKA targets the protein to the lysosome
Claudin-16 known as paracellin, concentrates at the TJ of the
thick ascending limb of Henle (TAL) and functions as a para-
cellular pore for Mg2+ [22]. This action is crucial for Mg2+
homeostasis because Mg2+ filtrated in the glomeruli is
predominantly reabsorbed by the paracellular pathway in the
TAL [219]. Claudin-16 is phosphorylated by PKA at Ser217
under physiological conditions and this phosphorylation is
essential for its localization at TJs, as dephosphorylated claudin-
16 and the Ser217Ala mutant are translocated into the lysosome
[99]. Ser217 is not conserved in claudin-16 derived from otherspecies or in the carboxyl terminal tail of other human claudins
(Fig. 7C and F).
A human renal disease known as familial hypomagnesemia
with hypercalciuria and nephrocalcinosis (FHHNC) is caused by
a disfunction of claudin-16 and is characterized by renal wasting
of Mg2+ and Ca2+ [22]. Patients with FHHNC exhibit diverse
mutations in claudin-16 that affect the intracellular traffic of this
protein. When proteins carrying these human mutations were
studied in MDCK cells, they were found to be retained in the
endoplasmic reticulum and to undergo proteosomal degradation
or to be delivered to lysosomes via clathrin-mediated endocy-
tosis following transport to the cell surface or without appearing
in the plasma membrane [220]. These mutations are located
in the extracellular loops and the transmembrane domains
of claudin-16, therefore they cannot be regulated by phosphor-
ylation. Other cases of lysosomal mistargeting are generated by
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domain where the critical Ser217 residue target of PKA is
located [221]. However, the absence of this residue is not the
only trigger for lysosomal mistargeting as mutations that disrupt
the PDZ binding motif of claudin-16 are also targeted to the
lysosome due to their inability to associate to the TJ scaffolding
protein ZO-1 [222,220].
4.2.4. PKA phosphorylation of Thr192 in claudin-3 perturbs
the barrier function of TJs
In cancerous tissue, the loss of the epithelial barrier function
has been recognized for a long time as an essential step involved
in cell transformation [223–227]. Therefore it has been intri-
guing to find claudin upregulation in several carcinomas (for a
review, see [7]), since these proteins are clearly implicated in TJ
formation and function. The answer to this conundrum is
apparently related to the phosphorylation state of claudins and
their cis-associated proteins (on the membrane of the same cell).
Claudin-3 for example contains a putative PKA phosphorylation
site at Thr192 and is an excellent substrate of this kinase. When
the ovarian cancer cell line OVCA433 is transfected with a
claudin-3 that contains a Thr192Asp mutation that mimics the
phosphorylated state, TER does not develop in newly plated
monolayers and paracellular permeability increases in mature
cultures [97]. These results hence suggest that claudin-3 phos-
phorylation by PKA may provide a mechanism for the dis-
ruption of TJs in ovarian cancer even when claudin expression is
upregulated. Thr192 is not conserved in claudin-3 derived from
other animal species, or in the carboxyl tail of any of the other
human claudins (Fig. 7D and F).
4.2.5. Phosphorylation by MAPK of Thr203 in claudin-1 is
crucial for the barrier function of TJs
The putative MAPK kinase phosphorylation site located at
Thr203 in claudin-1 is required to promote the barrier function
of TJs as a Thr203Ala mutation decreases TER and increases
paracellular permeability in rat lung endothelial cells (RLE)
[228]. This Thr is conserved in claudin-1 from rat and mouse
but not in bovine, chicken and humans and is not found in other
human claudins (Fig. 7A and F).
4.2.6. Phosphorylation of claudins-1 and -4 by WNK enzymes
generates a chloride shunt in the distal nephron proposed to
contribute to the pathogenesis of pseudohypoaldosteronism
type II (PHAII)
PHAII is an autosomal dominant disorder characterized by
hypertension and high serum potassium levels (hyperkalemia).
Reduced renal H+ secretion is also commonly seen, resulting in
metabolic acidosis. The hypertension has been attributed to an
increased renal salt absorption and the hyperkalemia to a
reduced renal K+ excretion, despite normal glomerular filtration
and aldosterone secretion. Mutations in two homologous Ser/
Thr kinase genes named WNK1 and WNK4 [With No K(lysine)
kinase] are responsible for this disease [229]. Mutations in these
genes consist of large deletions in the first intron of WNK1 and
missense mutations that cluster within a short span of WNK4.
These kinases are expressed in the nephron at the distalconvoluted tubule and the collecting duct, segments involved
in salt, K+, and pH homeostasis. WNK1 is cytoplasmic, whereas
WNK4 localizes at TJs (Table 1). WNK4 downregulates the
activity of the apical thiazide-sensitive Na+-Cl− cotransporter
and the apical secretory K+ channel ROMK, the basolateral Na+-
K+-2Cl− cotransporter and the Cl−/HCO3
− exchanger (for a
review, see [230]). When the disease-causing mutants are stably
expressed in MDCK cells, they display a gain of function that
causes increased paracellular chloride permeability and an
enhanced phosphorylation of claudins.WNK4 has been found to
increase the phosphorylation of claudins-1 to -4 whereas with
WNK1mutants only the increased phosphorylation of claudin-4
in Thr residues has been explored [231,232]. The presence of
such a chloride shunt in the distal nephron is proposed to
contribute to the pathogenesis of PHAII. The enhanced
phosphorylation of claudins by mutant WNK4 is not due to an
increased kinase activity of the mutant, but to an augmented
claudin-WNK4 association. The YV PDZ-binding motif found
at the carboxyl terminal end most claudins (all except claudins-
11, -12, -13 and -16) is necessary for this interaction.
The observation that an increased phosphorylation of
claudins exerted by WNK 1 and 4 augments the paracellular
permeability of Cl−, highlights the importance of claudins as
therapeutic targets for controlling paracellular charge selectivity.
For instance it has been observed that aldosterone which in-
creases the abundance of WNK4 in mammalian kidney, induces
inMDCK cells the apical to basal passage of Cl− and promotes a
transient phosphorylation of claudin-4 in Thr residues [233].
4.2.7. Phosphorylation of claudin-4 at Tyr208 by EphA2
enhances paracellular permeability
Another interesting case is posed by the interaction of
claudins with the Eph family of receptor protein tyrosine kinases
and its ligands. Ephrin receptors and ligands are widely
expressed in epithelial cells and their overexpression has been
reported in various tumors. Eph receptors are classified in two
groups according to their preferential binding to ligands tethered
to the cell surface by a GPI anchor (ephrin A) or a
transmembrane domain (ephrin B). The interaction of claudin-
4, one of the most frequently overexpressed proteins in diverse
carcinomas, with EphA2 via their extracellular domains,
stimulates the kinase activity of EphA2 and leads to the
phosphorylation of claudin-4 at Tyr208. The phosphorylation of
this residue contained within the PDZ binding motif of the
molecule attenuates the association of claudin-4 with ZO-1,
decreasing as a result the integration of this claudin into sites of
cell–cell contact and enhancing paracellular permeability [234].
Tyr208 is conserved in claudin-4 from other animal species and
in human claudins-1 to -9, -14, -16, -17 and -20 (Fig. 7E and F).
The ligand of Eph receptors B named ephrin B1 is also
involved in epithelial adhesion as it interacts in MDCK cells
with claudins-1 or -4 on the same surface in cis, via the
extracellular domains of these proteins [235]. This interaction
that triggers the phosphorylation of ephrin B1 on Tyr residues is
markedly enhanced by the trans interaction of claudins upon
cell–cell contact formation. Interestingly ephrin B1 phosphor-
ylation that can be abolished by Src kinase inhibitors increases
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suggest that the overexpression of claudins in certain cancers
would trigger the phosphorylation of ephrin B1, a condition that
would in turn generate a leakier TJ.
4.3. Occludin
4.3.1. Expression of different occludin bands depends on the
state of cell–cell contact
Occludin resolves by SDS-PAGE, as several bands between
62 and 82 kDa. The lower bands of 62–65 kDa are detergent
soluble and phosphorylated in both Ser and Thr residues while
the higher ones are insoluble and correspond to forms of
phosphorylated occludin [236,237]. The non- or weak phos-
phorylated forms of occludin distribute along the basolateral
membrane while the highly phosphorylated occludin selectively
concentrates at the TJ [236].
In the absence of cell–cell contacts MDCK cells only express
the lower molecular weight bands. Instead upon TJ formation
triggered by switching the cells from low to normal Ca2+ media,
higher molecular weight bands are expressed [238]. Somewhat
similar changes have been observed during the development of
mouse embryos, where occludin first assembles at the apico-
lateral membrane contact site during the 32-cell stage, just prior
to blastocoele cavitation [239]. At this time occludin switches
form a detergent soluble to an insoluble form indicative of
cytoskeletal anchorage. In mouse unfertilized eggs and embryos
at different stages of development three major bands of occludin
are detected. The lower and higher MW bands of 58 and 72–
75 kDa decline in intensity during development, whereas the 65-
to 67-kDa band increases in intensity from a minor band in eggs
to become the predominant band in blastocysts. Phosphatase
treatment has revealed that in blastocysts, the 72–75 and 58 kDa
bands are unphosphorylated, while the 65- to 67-kDa band is
strongly phosphorylated. In amphibian cells a different situation
is encountered, as occludin dephosphorylation correlates with TJ
assembly [240]. Thus in Xenopus laevis oocytes, occludin is in a
phosphorylated form, while fertilization and early embryo
development are associated with an electrophoretic downshift
of occludin that can be mimicked with phosphatase treatment.
4.3.2. Occludin phosphorylation diminishes during
TJ disassembly
In mammalian cells, the overall phosphorylation of occludin
is reduced during TJ disassembly, triggered by incubation of the
cells in low Ca2+ media or by treatment with phorbol esters
[237], or by infection with EPEC [241] orCampylobacter jejuni,
a leading cause of enterocolitis often associated with post-
infectious complications including irritable bowel syndrome and
Guillain–Barré syndrome [242], andBurkholderia cenocepacia,
an opportunistic bacteria that in patients with cystic fibrosis
traverses the airway epithelium causing bacteremia and sepsis
[243].
In cervical epithelium treatment with ATP or diC8, an agonist
of conventional and novel PKCs, decreases TJ resistance and
generates a breakdown of the 65-kDa occludin to the 50-kDa
form. ATP also decreases Thr phosphorylation of the 65-kDaform and increases Thr phosphorylation of the 50-kDa form and
Tyr phosphorylation of the 65- and 50-kDa forms [244]. PMA,
an activator or conventional and novel PKCs, is remarkable as
independently of the cell line used and on its effect on TJs, it
promotes Thr dephosphorylation of occludin, suggesting that it
targets a Ser/Thr phosphatase which then acts upon occludin
[245,76,70].
In Caco-2 cells the phosphorylation of occludin in Thr
residues, but not on Ser residues, is reduced during the dis-
assembly of TJs and is gradually increased during reassembly
[126], and in LLC-PK1 cells exposure to phorbol esters induces
disruption of the TJ associated to a rapid decrease in Thr
phosphorylation of occludin [245]. These results contrast with
others done in MDCK cells, that show a 71-kDa band of
occludin exclusively phosphorylated on Ser residues, that is not
present when the TJ is opened by Ca2+ removal [237]. The
discrepancy could be due to cell-type-dependent differences or
to the fact that while in the MDCK studies TJ were disrupted by
long-term exposure to low Ca2+; in the Caco-2 cell system a
short exposure to the Ca2+ chelator EGTAwas performed.
4.3.3. VEGF induces the breakdown of the blood–retinal
barrier (BRB) and triggers occludin phosphorylation
In retinal endothelial cells (REC), exposure to high glucose
results in increased expression of VEGF, as well as the
phosphorylation of VEGF receptor-2 (VEGFR-2) [246].
VEGF induces the breakdown of the blood–retinal barrier
(BRB) and triggers rapid phosphorylation of occludin and ZO-1
[247]. Accordingly REC of diabetic animals show an elevated
occludin phosphorylation [248]. Corticosteroids increase resis-
tance and intraocular pressure [249] and in REC decrease both
paracellular flux and occludin phosphorylation [250].
The signaling pathways that underlie VEGF signaling are
beginning to be unraveled. Thus, in aortic endothelial cells,
VEGF enhances permeability by sequentially involving Src,
ERK, JNK and PI-3 kinase/Akt. This leads to the Ser/Thr
phosphorylation and redistribution of ZO-1 and occludin. Atrial
natriuretic peptide (ANP) inhibits VEGF signaling and TJ
protein phosphorylation by interaction with both guanylate
cyclase and natriuretic peptide clearance receptors [251].
4.3.4. Rho/ROCK and MLCK signaling regulates occludin
phosphorylation
The expression of a dominant negative Rho mutant causes a
reduction of the slower migrating, more highly phosphorylated
occludin isoforms, whereas a constitutively active Rho mutant
causes accumulation of the highly Ser/Thr phosphorylated
occludin isoforms [132].
In brain endothelial cells Rho/ROCK signaling causes BBB
impairment that involves occludin and claudin-5 phosphoryla-
tion in Ser and Tyr residues [252] (Fig. 3). This process appears
to be the underlying cause of BBB impairment that allows
monocytes migration into the brain during HIV-1 encephalitis.
The potent chemokine monocyte chemoattractant protein CCL2
increases BBB permeability, redistributes TJ proteins and
generates de novo Ser/Thr phosphorylation of occludin, ZO-1,
ZO-2 and claudin-5. cPKCα and aPKCζ participate in this event,
748 L. González-Mariscal et al. / Biochimica et Biophysica Acta 1778 (2008) 729–756being cPKCα a downstream target for RhoA. Thus brain endo-
thelial permeability can be regulated by monocyte chemoat-
tractant proteins that directly activate aPKCζ or that, through
Rho activation, activate cPKCα and ROCK [253] (Fig. 3).
Other substances known to increase endothelial permeability
and to promote the phosphorylation of TJ proteins including
occludin and claudin-5 are ethanol and its metabolite acetalde-
hyde [254], as well as oxidative stress stemming from ethanol
metabolism [255]. Alcohol induced disruption of the BBB
enhances monocytes migration across brain endothelial cells,
due to the activation of MLCK that triggers the phosphorylation
of MLC and TJ proteins. Lysophosphatidic acid (LPA), a
molecule secreted from activated platelets, and histamine
trigger the disappearance of perijunctional actin and MLC
phosphorylation. Interestingly while LPA activates RhoA and
its target ROCK, histamine can increase occludin phosphory-
lation in a manner independent of both RhoA and ROCK [256].
4.3.5. Occludin is a phosphorylation target of nPKCδ and
casein kinases 2 and Iε
In MDCK cells the inhibition of nPKCδ with rottlerin blocks
occludin phosphorylation and the formation of the TJ barrier
[44]. Thus, treatment of mammalian epithelial cells with the
non-phorbol ester agonist of conventional and novel PKCs,
bryostatin-1 leads to the appearance of a higher molecular
weight form of occludin and increases the barrier function of TJs
[81]. Although the precise site of action of nPKCδ on occludin
remains unknown, it was previously reported that Ser338 is an
in vitro PKC phosphorylation site [257].
Another Ser/Thr kinase involved in occludin phosphorylation
is casein kinase 2 (CK2). This kinase phosphorylates two
residues that are highly conserved in several species (Thr375
Xenopus/403 mouse/405 rat/404 human/403 dog and Ser379
Xenopus/407 mouse/409 rat/408 human/407 dog) [258,259].
Casein kinase Iε (CKIε) also phosphorylates occludin and co-
localizes and co-immunoprecipitates with occludin from human
endothelial cells (Table 1). The regions of occludin sufficient for
CKIε binding and phosphorylation are located upstream of the
CK2 phosphorylation sites [260]. The impact of occludin
phosphorylation by CK2 and CKIε on TJ function is not yet
known.
4.3.6. Tyrosine phosphorylation of occludin compromises
barrier integrity of TJs
Tyrosine phosphorylation regulates occludin function. For
example, treatment of retinal pigment epithelial cells (RPE)
with HGF [213] and of brain capillaries and human colonic
biopsies with Tyr phosphatase inhibitors [261,262] compro-
mises the barrier integrity of the TJ and increases occludin Tyr
phosphorylation. In endothelial cells the hemodynamic force of
cyclic circumferential strain decreases permeability and occlu-
din tyrosine phosphorylation and promotes localization of
occludin and ZO-1 to the cell borders [263], while shear stress
increases hydraulic conductivity and occludin phosphorylation
[264].
Moreover, disruption of the BBB by cerebral ischemia [265],
or by exposure to glutamate [266], an amino acid that increasesdramatically in cerebral ischemia and stroke, augments Tyr
phosphorylation of occludin. This process is coincident with an
increase in the activity of c-Src [265] and FAK [261] tyrosine
kinases.
In endothelial cells oxidative stress and oxidized phospho-
lipids increase paracellular permeability and occludin phosphor-
ylation [267]. In epithelial cells, oxidative stress triggers TJ
impairment, tyrosine phosphorylation of occludin and ZO-1,
their dissociation from the actin cytoskeleton and redistribution
from the junctional area, and reduces their co-immunoprecip-
itation [211,209]. Oxidative stress induces activation and
membrane translocation of c-Src [210]. In vitro tyrosine
phosphorylation of the carboxyl terminal tail of occludin by c-
Src attenuates the ability of occludin to bind ZO-1, ZO-2 and
ZO-3, thus suggesting that c-Src-mediated disruption of TJs
involves Tyr phosphorylation of occludin [268]. Oxidative stress
also increases the association of occludin with PI3K. The latter is
involved in the oxidative stress induced disruption of TJs [209].
In contrast to the abovementioned results that reveal a
deleterious effect of Tyr phosphorylation on TJ integrity, during
TJ assembly induced in MDCK cells by ATP [208] or Ca2+
repletion, occludin becomes Tyr phosphorylated by the action
of the non-receptor tyrosine kinase c-Yes [269] (Table 1).
5. Concluding remarks
TJs are dynamic structures regulated by the crosstalk of
diverse signaling pathways, whose action varies according to
the cellular environment. The availability of stimulators and
inhibitors of different steps in the signaling cascades, of
dominant active and negative Rho mutants, and of TJ proteins
with point mutations at putative phosphorylation sites has
ascertained the participation of multiple kinases and phospha-
tases in finely tuning TJ stability. The identification of TJ
proteins as targets of multiple kinases activated under diverse
pathological conditions might allow the design of new the-
rapeutic strategies for the treatment of a broad spectrum of
human diseases.
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